Although these data suggest targeting stroke‐associated deficits in circulating IgM concentration may be a novel therapeutic strategy to reduce post‐stroke pneumonia, it is important to acknowledge some caveats of the current study and highlight the need for next‐stage pre‐clinical trials to address important translation‐relevant questions. The gene discussed is CD40LG; the disease is pneumonia.